Nabriva Therapeutics plc
NBRV
Kedudukan dalam Saham
#39899
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Harga Saham
$0.63
Disegerakkan terakhir: 2023-08-29
Modal Pasaran
$284.20K
Perubahan (1 hari)
-21.25%
Perubahan (1 tahun)
629,900.02%
Negara
IE
Perdagangan Nabriva Therapeutics plc (NBRV)
Kategori
Healthcare
Sejarah harga saham bagi Nabriva Therapeutics plc (NBRV)
Harga penutupan tertinggi: $0.00 pada 2026-10-01
Harga penutupan terendah: $0.74 pada 2023-08-01
Harga penutupan terendah: $0.74 pada 2023-08-01
Sejarah harga saham Nabriva Therapeutics plc dari 2023 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | 60.55% |
| 2024 | 9.75% |
| 2023 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
